Evaluation of mutagenic and anti-mutagenic potential of alpha-lipoic acid by chromosomal aberration assay in mice
This study investigated both the mutagenicity and anti-mutagenicity of alpha-lipoic acid (ALA) in the bone marrow cells of mice using a chromosomal aberration assay. Cyclophosphamide (CP) 40 mg/kg was used as a clastogen in the positive control, and a vehicle-treated negative control group was also included. Multiple dose levels (15, 30, and 100 mg/kg of ALA) were given by intraperitoneal injection (IP) alone and in combination with CP (CP was administered 1 h prior to ALA). Bone marrow samples were collected 12 and 24 h after drug administration. The results demonstrated a significant increase in the frequency of chromosomal aberrations (CA) in bone marrow cells with depressions in the mitotic index (MI) of the positive control group of mice. However, in the groups of mice treated with different doses of ALA in the presence of CP, the percentages of CA decreased significantly with increases in mitotic activity. The results also indicate that ALA given alone in different doses had no mutagenic effect on mouse bone marrow cells. ALA has a dose and time-dependent protective effect against the mutagenicity induced by CP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Drug and chemical toxicology - 43(2020), 4 vom: 10. Juli, Seite 378-382 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tripathi, Rina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
73Y7P0K73Y |
|---|
| Anmerkungen: |
Date Completed 10.03.2021 Date Revised 10.03.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/01480545.2019.1606231 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296913901 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296913901 | ||
| 003 | DE-627 | ||
| 005 | 20231225090848.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/01480545.2019.1606231 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0989.xml |
| 035 | |a (DE-627)NLM296913901 | ||
| 035 | |a (NLM)31072146 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tripathi, Rina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of mutagenic and anti-mutagenic potential of alpha-lipoic acid by chromosomal aberration assay in mice |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.03.2021 | ||
| 500 | |a Date Revised 10.03.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study investigated both the mutagenicity and anti-mutagenicity of alpha-lipoic acid (ALA) in the bone marrow cells of mice using a chromosomal aberration assay. Cyclophosphamide (CP) 40 mg/kg was used as a clastogen in the positive control, and a vehicle-treated negative control group was also included. Multiple dose levels (15, 30, and 100 mg/kg of ALA) were given by intraperitoneal injection (IP) alone and in combination with CP (CP was administered 1 h prior to ALA). Bone marrow samples were collected 12 and 24 h after drug administration. The results demonstrated a significant increase in the frequency of chromosomal aberrations (CA) in bone marrow cells with depressions in the mitotic index (MI) of the positive control group of mice. However, in the groups of mice treated with different doses of ALA in the presence of CP, the percentages of CA decreased significantly with increases in mitotic activity. The results also indicate that ALA given alone in different doses had no mutagenic effect on mouse bone marrow cells. ALA has a dose and time-dependent protective effect against the mutagenicity induced by CP | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Alpha-lipoic acid | |
| 650 | 4 | |a anti-mutagenic | |
| 650 | 4 | |a antioxidant | |
| 650 | 4 | |a chromosomal aberration | |
| 650 | 4 | |a cyclophosphamide | |
| 650 | 4 | |a mitotic index | |
| 650 | 7 | |a Alkylating Agents |2 NLM | |
| 650 | 7 | |a Thioctic Acid |2 NLM | |
| 650 | 7 | |a 73Y7P0K73Y |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 700 | 1 | |a Banji, David |e verfasserin |4 aut | |
| 700 | 1 | |a Tripathi, Pankaj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug and chemical toxicology |d 1984 |g 43(2020), 4 vom: 10. Juli, Seite 378-382 |w (DE-627)NLM000913685 |x 1525-6014 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:4 |g day:10 |g month:07 |g pages:378-382 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/01480545.2019.1606231 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 4 |b 10 |c 07 |h 378-382 | ||